A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer | Zendy

Jalid Sehouli | Zendy; Oumar Camara | Zendy; Sven� Mahner | Zendy; Thomas Bauknecht | Zendy; W. Lichtenegger | Zendy; Ingo B. Runnebaum | Zendy; Katherine Y. Look | Zendy; Fritz Jaenicke | Zendy; Guelten Oskay-Oezcelik | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer

Author(s) -

Jalid Sehouli,

Oumar Camara,

Sven� Mahner,

Thomas Bauknecht,

W. Lichtenegger,

Ingo B. Runnebaum,

Katherine Y. Look,

Fritz Jaenicke,

Guelten Oskay-Oezcelik

Publication year - 2010

Publication title -

cancer chemotherapy and pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.112

H-Index - 111

eISSN - 1432-0843

pISSN - 0344-5704

DOI - 10.1007/s00280-009-1230-3

Subject(s) - pemetrexed , carboplatin , medicine , ovarian cancer , oncology , adverse effect , thymidylate synthase , phases of clinical research , toxicity , chemotherapy , pharmacology , urology , cancer , cisplatin , fluorouracil

Carboplatin-based combinations are established in platinum-sensitive recurrent ovarian cancer. To improve the therapeutic index, new platinum-based combinations are required. Pemetrexed is a multi-targeted antifolate inhibiting thymidylate synthase. The aim of this study was to determine the maximally tolerated dose (MTD) and dose-limiting toxicity (DLT) and to characterize toxicities of the combination of pemetrexed (Pem) and carboplatin (Cb).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research